
One of Denmark’s most ambitious biotech companies, Symphogen, has resumed full control of one of its most promising candidate drugs, the monoclonal antibody Sym004. The move signals the end of the company’s R&D pact with Germany’s Merck KGaA and Symphogen will now have to go it alone with its oncology contender.
"We are pleased to have regained the rights to this attractive product candidate,” Symhogen’s CEO Kirsten Drejer says in a press release.
Allerede abonnent? Log ind.
Læs hele artiklen
Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
- Adgang til alle låste artikler
- Modtag vores daglige nyhedsbreve
- Fuld adgang til vores app